Immunocellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017
ImmunoCellular Therapeutics, Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported loss before other income was $11,341,867 against $5,483,037 a year ago. Interest income was $381 against $6,397 a year ago. Net loss was $3,609,148 against $5,329,571 a year ago.
For the period, the company reported loss before other income was $16,820,765 against $11,320,444 a year ago. Interest income was $4,175 against $8,911 a year ago. Net loss was $9,434,135 against $10,962,916 a year ago. The company used $9.5 million of cash in operations for the six months ended June 30, 2017, compared to $11.2 million for the six months ended June 30, 2016.